The novel, telomerase-directed, telomere-targeted, anticancer agent 6-thio-dG (THIO) demonstrates potent activity and induces antitumor immunity in hepatocellular carcinoma (HCC) models
Shay, J., Mender, I., Siteni, S., Obrocea, M., Vitoc, V., Gryaznov, S.
Published in European journal of cancer (1990) (01.10.2022)
Published in European journal of cancer (1990) (01.10.2022)
Get full text
Journal Article
1493P A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Jankowski, T., Sótér, S., Raumlau, R., Chilingirova, N., Cholakova, M.D., Seidl, B., Moore, M., Joshi, R., Vitoc, V., Zaporojan, V., Gryaznov, S., Watkins, P., Obrocea, M.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article